We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 55% below its sector, cheaper than its peers on earnings.
Tonghua Dongbao Pharmaceutical Co., Ltd. is a Chinese enterprise primarily engaged in the research, development, manufacturing, and commercialization of pharmaceutical products. These therapeutics are designed to address diabetes and various cardiovascular conditions within the Chinese market. Its operations are structured across two distinct divisions: pharmaceuticals and building materials. The company's extensive pharmaceutical portfolio features prominent insulin analogues, including insulin glargine, insulin aspart, and insulin lispro. Furthermore, it offers a range of antidiabetic medications, oral hypoglycemic drugs, and medical devices such as Gan Shulin pens and blood glucose meters. Tonghua Dongbao also maintains a strategic partnership with Adocia. Established in 1985, the company is headquartered in Tonghua, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 600867.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
